Results 21 to 30 of about 6,143,169 (374)

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink   +6 more
wiley   +1 more source

„Cum trăim este atât de departe de cum ar trebui să trăim”: contemporaneitatea lui Machiavelli [PDF]

open access: yesPolis: Revista de Stiinte Politice, 2021
Interview with Georgios ...
Jozef Matula
doaj  

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

The battle for the whistleblower : an interview with John Kiriakou [PDF]

open access: yes, 2019
Whistleblowing, or speaking truth to power, is complex. How truth telling is shaped is an important issue, as is the legitimacy of the individual who speaks out.
Bushnell, Alexis   +2 more
core  

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

open access: yesMolecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha   +6 more
wiley   +1 more source

Andres Quintero Interview [PDF]

open access: yes, 2014
Andres Taborda ’15 and Jennifer Giffels ’14 of the Model OAS course in the Department of Political Science interviewed Andres Quintero, who is an expert in peace and conflict resolution.
Giffels, Jennifer, Taborda, Andres
core   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

Interview from Australia [PDF]

open access: yes, 2018
While still in the midst of their study abroad experiences, students at Linfield College write reflective essays. Their essays address issues of cultural similarity and difference, compare lifestyles, mores, norms, and habits between their host countries
Bradley, Mikayla
core   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

open access: yesMolecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy